[go: up one dir, main page]

WO2000072853A1 - Composition chimique, son procede de fabrication et sa methode d'utilisation pour traiter le cancer - Google Patents

Composition chimique, son procede de fabrication et sa methode d'utilisation pour traiter le cancer Download PDF

Info

Publication number
WO2000072853A1
WO2000072853A1 PCT/RO1999/000014 RO9900014W WO0072853A1 WO 2000072853 A1 WO2000072853 A1 WO 2000072853A1 RO 9900014 W RO9900014 W RO 9900014W WO 0072853 A1 WO0072853 A1 WO 0072853A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
product
medication
cell
boric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RO1999/000014
Other languages
English (en)
Inventor
Corneliu M. Niculescu
Corneliu C. Niculescu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2000072853A1 publication Critical patent/WO2000072853A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds

Definitions

  • the object of invention refers to-
  • Appliance range of the product is cancer disease medication as a chemoterapy treatment.
  • Cancer chemoterapy also known as cytostatics enables the evolution delay of different neoplasical affections.
  • haematopoetic tissue cancer is relatively sensible and cancer tumor hardly sensible to chemoterapy, which does not save the patient life but scarcely improve his condition for an certain period of time, as additional medication beside the specific classical cancer treatment (surgery and radiotherapy) .Cytostatics do not destroy the cancer cell but slow down its evolution
  • the above mentioned substances are toxic, having side haematological effects, the harmful effects entailing mouth and intestine mucous membranes lesion, lever lesions, baldness, hypogonadism and immunology weakening which develop proper conditions for infections spreading. Furthermore, the price of these products is significantly high.
  • the procaine chlorine hydrate dose allowed for 24 hours is of 250 mg, boric acid dose being of 3,000 mg
  • Toxic noxious dose of procaine chlorine hydrate is of 2,500 mg and of boric acid of
  • Medication doses of our product are as follows 18mg of procaine chlorine hydrate per day and 54 mg boric acid per day
  • our product may be included within hemaeopatic medication products lacking toxicity
  • cancer cell induces deviations usually at nucleic acid level resulting in a mutation of genetic information, which determines the incapacity to control the cell metabolism and implicitly cells sizes and multiplication Consequently for this uncontrolled development, the cancer cell needs additional phosphoric acid (acid standing for the basis of nucleic acids) which is absorbed in very large quantities, even if its level in human organism is generally low
  • phosphoric acid ascid standing for the basis of nucleic acids
  • the boric acid replaces the phosphoric acid within the cancer cell metabolism, being , let us say, fond of it destroying it.
  • the normal cells of human body, other than cancer affected ones do not mistake the identification of the two acids, therefore they are not affected.
  • procaine chlorine hydrate has an anesthetic effect, determines blood vessel expansion, controls the plane muscles, enhances the tissues nutrition and it is a inter - cell free radicals inhibitor.
  • Cancer cells as well as ordinary old cells have a higher concentration of free radicals - idea agreed by dr. ASLAN as well when she introduced procaine chlorine hydrate in the composition of GEROVITAL Free radicals inhibition inside the cancer cell leads to a significant lowering of its vitality, as well as of its secretions, noxious to the organism. We consider it as well causes the cancer cell to mistake the identification of boric acid instead of phosphoric acid, and determines self-destruction.
  • the product is recommended in all cancer locations and stages of disease either as a single medication or together with any other classical treatment (surgery or chemotherapy).
  • the product medication is oral, following the quantities:
  • the treatment lasts two years, no matter the fact that the disease symptoms disappeares mean time and the laboratory tests and other medical investigations prove to have normalized the health condition.
  • the medication is associated w ; ⁇ n Po ⁇ dm muscle injected one ampouie D ⁇ ⁇ ay in series of 3 days consecutively at a period of 2 distance and V ⁇ amin C 200mg daily for own immunity system stimulation
  • the hereunto invention refers to a chemical medicament, a fabrication procedure and medication methodology on its basis, in case of cancer diagnostic
  • the active ingredients of the product modify the abnormal metabolism of cancer cell, determining its destruction
  • this innovation determines the production of cancer cell cytoiysis without being toxic to the human body and which allows parallel cancer classical medication, furthermore it determines a positive influence of classical medication

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un médicament chimique, ainsi que son procédé de fabrication et sa méthode d'utilisation, notamment pour traiter le cancer. Ce médicament renferme de l'acide borique, destiné à remplacer l'acide phosphorique dans les noyaux cellulaires, du chlorhydrate de procaïne qui déséquilibre le métabolisme des cellules touchées par le cancer grâce à une régulation des radicaux libres, et une solution saline normale servant de milieu de circulation. Les principes actifs de ce produit modifient ainsi le métabolisme anormal des cellules cancéreuses et assurent leur destruction. Cette invention sert également en chimiothérapie à soumettre les cellules cancéreuses à une cytolyse, sans effet toxique pour le corps humain. Enfin, le médicament de cette invention permet de traiter le cancer de manière traditionnelle, en enrayant toute progression de ce dernier.
PCT/RO1999/000014 1999-05-26 1999-09-23 Composition chimique, son procede de fabrication et sa methode d'utilisation pour traiter le cancer Ceased WO2000072853A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RO99-00605 1999-05-26
RO99-00605A RO116524B1 (ro) 1999-05-26 1999-05-26 Produs farmaceutic antineoplazic, uman şi veterinar, procedeu de obţinere şi metodă de tratament antineoplazic

Publications (1)

Publication Number Publication Date
WO2000072853A1 true WO2000072853A1 (fr) 2000-12-07

Family

ID=20107309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RO1999/000014 Ceased WO2000072853A1 (fr) 1999-05-26 1999-09-23 Composition chimique, son procede de fabrication et sa methode d'utilisation pour traiter le cancer

Country Status (2)

Country Link
RO (1) RO116524B1 (fr)
WO (1) WO2000072853A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028550A1 (fr) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Anesthesiques topiques employes dans le traitement du cancer, les affections auto-immunes et l'ischemie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2459659A1 (fr) * 1979-06-23 1981-01-16 Centrala Ind Medicamente Nouvelle association anti-cancereuse et son procede de preparation
HUP9601450A1 (hu) * 1996-05-30 1998-06-29 Benedek Juhász Eljárás sejtburjánzással járó tünetegyüttest befolyásoló készítmény előállítására

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2459659A1 (fr) * 1979-06-23 1981-01-16 Centrala Ind Medicamente Nouvelle association anti-cancereuse et son procede de preparation
HUP9601450A1 (hu) * 1996-05-30 1998-06-29 Benedek Juhász Eljárás sejtburjánzással járó tünetegyüttest befolyásoló készítmény előállítására

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199840, Derwent World Patents Index; AN 1998-459642, XP002133589, JUHASZ BENEDEK: "Process for producing pharmaceutical composition for treating neoplasmic syndromas" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028550A1 (fr) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Anesthesiques topiques employes dans le traitement du cancer, les affections auto-immunes et l'ischemie
US6391888B1 (en) 1999-10-15 2002-05-21 Mayo Foundation For Medical Education And Research Topical anesthetics useful for treating cancer

Also Published As

Publication number Publication date
RO116524B1 (ro) 2001-03-30

Similar Documents

Publication Publication Date Title
Friedman et al. Primary hypomagnesaemia with secondary hypocalcaemia in an infant
WO1984002470A1 (fr) Preparation medicinale pour le traitement therapeutique d'ulceres peptiques
WO2000072853A1 (fr) Composition chimique, son procede de fabrication et sa methode d'utilisation pour traiter le cancer
CN109395068A (zh) 一种难愈创口专用消毒液
US5391575A (en) Method for treating neurofibromatosis
AU2021102411A4 (en) Telomerase Balancer
CN1060336C (zh) 一种防治钙质缺损的药物及其制备方法
US20100029590A1 (en) Methods for treating or preventing hemorrhagic cystitis using a glycerophosphate salt
Dolezal et al. Treatment of the patient with extensive osteoradionecrosis of the mandible
RU2053765C1 (ru) Лекарственное средство для профилактики простудных заболеваний у детей
WO2009100591A1 (fr) Utilisation d'acide chlorhydrique pour la fabrication d'un médicament pour le traitement d'une maladie vasculaire
Novak et al. INFLUENCE OF ULTRAVIOLET IRRADIATION ON CALCIUM CONTENT OF BLOOD SERUM: IN HAY-FEVER, HYPERESTHETIC RHINITIS AND THE ASTHMAS: PRELIMINARY REPORT
Wilson et al. Renal hypophosphatemia
EP2051717B1 (fr) Chirurgie cardiaque remplacee par des micronutriments
RU2246303C2 (ru) Способ фармакологической коррекции дефицита кальция у больных остеопорозом
Wyman et al. The organization of a special clinic: For the treatment of rickets with the mercury vapor quartz lamp in an outpatient department
WO1991000098A1 (fr) Preparation anti-inflammatoire et son procede d'obtention
EP2085091B1 (fr) Utilisation d'acide chlorhydrique dans la fabrication de médicament destiné au traitement de diabète
RU2349322C2 (ru) Способ лечения механической желтухи
Morozov et al. The effect of 60-day administration of sodium benzoate and mexidol on the ultrastructure of the regenerate formed in the rat's tibiae
Jacobi Therapeutics of infancy and childhood
CN120617240A (zh) 安五脂素在制备治疗或预防神经炎症相关疾病、骨癌痛的药物中的应用
RU2299739C2 (ru) Фитоминеральное средство и способ его применения
Bahadori et al. A rare case report of acute vitamin D toxicity due to suicide attempt
Al-Juburi et al. Efficacy of Senna Leaves Extract and Rosuvastatin on Blood Parameters of Inducing Hyperlipidemia Laboratory Rats.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA IL TR US ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase